HEALTHAug 5 · 14:59 UTCCNBC TOP

Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says

Bank of America spends $250 million annually on GLP-1 drugs for its employees, according to the CEO. Employers face challenges due to rising demand for costly GLP-1 medications like Ozempic and Wegovy.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Bank of AmericaorganizationGLP-1 drugstopicOzempictopicWegovytopicCEOperson

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJul 18 · 16:23 UTC
Ozempic nation: America’s GLP-1 use nearly quadruples in just two years
HEALTHJul 27 · 19:32 UTC
Why cutting GLP-1 benefits could be a costly mistake for companies
HEALTHApr 16 · 01:24 UTC
This CEO wants to cover weight loss drugs for employees. They're just too expensive.
HEALTHMay 28 · 19:08 UTC
Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
HEALTHJun 11 · 13:21 UTC
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
HEALTHJul 27 · 14:02 UTC
Compounded GLP-1 drugs creating concern among doctors and FDA